## AMENDED IN SENATE JULY 3, 1997 AMENDED IN ASSEMBLY MAY 20, 1997 AMENDED IN ASSEMBLY APRIL 7, 1997

CALIFORNIA LEGISLATURE—1997-98 REGULAR SESSION

## ASSEMBLY BILL

No. 764

## **Introduced by Assembly Member Davis**

February 26, 1997

An act to amend Sections <del>110403, 111635, and 111655</del> *110165, 110305, 110403, 110405, and 111635* of, and to repeal Section <del>110305</del> *110408* of, the Health and Safety Code, relating to food and drugs.

## LEGISLATIVE COUNSEL'S DIGEST

AB 764, as amended, Davis. Food and drug inspections.

Existing law, the Sherman Food, Drug, and Cosmetic Laws, requires the State Department of Health Services to cause a special investigation of the preparation and sale of drugs and food and their adulteration. Existing law also requires the department to perform duties that are required by law for the detection and prevention of the adulteration of articles used for food and drink, and for the punishment of persons who are found guilty of violating any law providing against their adulteration.

Existing law provides that it is unlawful for any person to use to his or her own advantage, or to reveal to any person other than to the director, officers, or employees of the department, or to the courts when relevant in any judicial proceeding AB 764 — 2 —

under the Sherman Food, Drug, and Cosmetic Laws, any information acquired under authority of that law concerning any method or process which as a trade secret is entitled to protection.

This bill would permit an authorized agent of the department to receive the trade secret information. The bill would authorize the department to reveal trade secret information in connection with the responsibilities of the department under the Sherman Food, Drug, and Cosmetic Laws, to any employee of the federal Food and Drug Administration who is authorized in writing by the Chief of the Food and Drug Branch of the department or his or her designee to receive this type of information. The employee receiving this type of information would be subject to certain procedures relating to maintaining the confidentiality of the information.

Existing law provides that it is unlawful for any person to use on the labeling of any drug or device, or any advertisement relating to any drug or device, any representation or suggestion that an application is effective under a prescribed provision of law relating to new drugs and devices or that the drug or device complies with that law.

This bill would repeal that provision revise this provision to no longer apply to an advertisement relating to any drug or device.

Existing law provides that it is unlawful for any person to advertise any drug or device represented to have any effect in enumerated conditions, disorders, or diseases.

This bill would create an exception to that provision if the advertisement is in compliance with prescribed federal law.

Under existing law, it is unlawful for any person to disseminate any false advertisement of any food, drug, device, or cosmetic. Existing law provides that an advertisement of a drug or device represented to have an effect in enumerated conditions, disorders, or diseases is not unlawful, under this and other provisions, if it is disseminated only to members of medical, dental, pharmaceutical, or veterinary professions, or appears only in the scientific periodicals of these professions, or is disseminated only for the purpose of public health education by persons not commercially

\_3\_ AB 764

interested, directly or indirectly, in the sale of drugs or devices.

This bill would provide that an advertisement that a drug or device has a specific curative or therapeutic effect on the enumerated conditions, disorders, or diseases mentioned above is not unlawful under these provisions if the drug or device is approved or cleared for marketing for that specific curative or therapeutic effect through any one of designated means.

Existing law provides that whenever the department determines that an advance in medical science has made any type of self-medication safe and effective as to any of the enumerated conditions, disorders, or diseases mentioned above, the department shall, by regulation, authorize the advertisement of that drug or device as having a curative or therapeutic effect for the disease, subject to conditions and restrictions as the department may consider necessary to the interests of public health.

This bill would repeal this provision.

Existing law requires the department to inspect each place of business for the manufacture of any drug or device prior to issuing *a license* or renewing an annual *a* license annually.

This bill would instead require the department to make that inspection once every 2 years. The bill would provide that this provision shall not affect the requirement to complete a license application annually accompanied by an application fee:

This bill would delete the requirement that the department inspect each place of business prior to renewing an annual license. The bill would require the department, in addition to the inspection prior to issuing an initial license, to inspect the place of business once every 2 years. The bill would require the department to use the information obtained during an inspection conducted within the previous 2 years by the United States Food and Drug Administration and would authorize the department to use, in lieu of all or part of any inspection required under these provisions, information from audits conducted pursuant to various quality system standards or other information identified by the department by regulation.

**AB 764 - 4** —

7

11

13

15

Existing law prohibits any person from manufacturing any drug or device without a license from the department and exempts from that licensure requirement certain entities.

This bill would also exempt from licensure any person who has registered an establishment and listed all products in compliance with a prescribed federal law and submits a copy of the federal registration and listing to the department in accordance with regulations established by the department.

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no.

*The people of the State of California do enact as follows:* 

- SECTION 1. The Legislature finds and declares all of 1 the following:
- (a) The medical technology 3 industry, encompassing biotechnology and medical device and equipment manufacturing, is a rapidly growing California industry, and is critical to the future health of California's economy.
- (b) This industry produces therapeutic drugs, medical devices. equipment, and diagnostic transforming the practice of medicine and improving the 10 lives of millions of patients around the world.
- (c) The majority of the companies comprising this 12 sector are small businesses who must invest heavily in research and development for several years before they market their first product, and who are heavily impacted by federal and state regulation.
- (d) The businesses that comprise this industry are 16 subject to rigorous health and safety regulation by both 17 18 the U.S. Food and Drug Administration (FDA), which maintains primary jurisdiction over this industry. and the 20 Food and Drug Branch of the State Department of Health Services. 21
- 22 (e) The Legislature should, to the extent possible, seek 23 to reasonably reform state laws and regulations that duplicate federal laws and regulations with respect to this industry, with the goal being to eliminate duplicative procedures which add no value to consumers. Additional goals of the Legislature include to harmonize state and

**—5— AB 764** 

1 federal regulatory requirements, promote federal-state planning and information sharing, and assure that state health protection resources are used in an efficient manner that maximizes public health protection.

SEC. 2. Section 110305 of the Health and Safety Code is repealed.

SEC. 3.

5

6

7

8

10

12 13

33

37

38

SEC. 2. Section 110165 of the Health and Safety Code is amended to read:

110165. It is unlawful for any person to use to his or her own advantage, or to reveal to any person other than to the director or, officers or, employees, or authorized agents of this department, or to the courts when relevant 14 in judicial proceeding under this any part, acquired under 15 information authority of this 16 concerning any method or process which as a trade secret 17 is entitled to protection. However, the department may 18 reveal trade secret information in connection with the 19 responsibilities of the department under this part, to any 20 employee of the federal Food and Drug Administration 21 who is authorized in writing by the Chief of the Food and 22 Drug Branch of the department or his or her designee to 23 receive this type of information. The employee receiving 24 this type of information shall be informed in writing of the 25 prohibitions under this section, shall agree in writing to 26 keep this information confidential, and shall be subject to 27 this section, Section 301(j) of the federal act (21 U.S.C. Sec. 331(j)), and any other provisions relevant to the 29 protection of trade secrets under California and federal 30 law.

31 SEC. 3. Section 110305 of the Health and Safety Code 32 is amended to read:

110305. It is unlawful for any person to use on the 34 labeling label of any drug or device, or any advertisement relating to any drug or device, any representation or 36 suggestion that an application with respect to the drug or device is effective under Section 111550 or that the drug or device complies with that section.

SEC. 4. Section 110403 of the Health and Safety Code 39 is amended to read:

AB 764 — 6 —

- 1 110403. It is unlawful for any person to advertise any
- 2 drug or device, except in compliance with subdivisions
- 3 (n) and (r) of Section 352 of Title 21 of the United States
- 4 Code the federal Food, Drug, and Cosmetic Act (21
- 5 U.S.C. Sec. 301 et seq.) and the Federal Trade
- 6 Commission Act (15 U.S.C. Sec. 41 et seq.), represented
- 7 to have any effect in any of the following conditions,
- 8 disorders, or diseases:
- 9 (a) Appendicitis.
- 10 (b) Blood disorders.
- 11 (c) Bone or joint diseases.
- 12 (d) Kidney diseases or disorders.
- (e) Cancer.
- 14 (f) Carbuncles.
- 15 (g) Diseases, disorders, or conditions of the eye.
- 16 (h) Diabetes.
- 17 (i) Diphtheria.
- 18 (i) Gallbladder diseases or disorders.
- 19 (k) Heart and vascular diseases.
- 20 (l) High blood pressure.
- 21 (m) Diseases or disorders of the ear or auditory
- 22 apparatus, including hearing loss and deafness.
- 23 (n) Measles.
- 24 (o) Meningitis.
- (p) Mental disease or mental retardation.
- 26 (q) Paralysis.
- (r) Pneumonia.
- 28 (s) Poliomyelitis.
- 29 (t) Prostate gland disorders.
- 30 (u) Conditions of the scalp, affecting hair loss, or
- 31 baldness.
- 32 (v) Alcoholism.
- 33 (w) Periodontal diseases.
- 34 (x) Epilepsy.
- 35 (y) Goiter.
- 36 (z) Endocrine disorders.
- 37 (aa) Sexual impotence.
- 38 (ab) Sinus infections.
- 39 (ac) Encephalitis.
- 40 (ad) Tumors.

**—7— AB 764** 

- 1 (ae) Venereal diseases.
- 2 (af) Tuberculosis.
- 3 (ag) Ulcers of the stomach.
- 4 (ah) Varicose ulcers.
- 5 (ai) Scarlet fever.

6

9

14 15

17

19

21

22

23

24

34 35

36

37

39

- (aj) Typhoid fever.
- 7 (ak) Whooping cough.
- 8 (al) Acquired immune deficiency syndrome (AIDS).
  - (am) AIDS-related complex (ARC).
- (an) Diseases, disorders, or conditions of the immune 10 11
- 12 SEC. 4. Section 111635 of the Health and Safety Code 13 is amended to read:
  - 111635. The department shall inspect each place of business once every two years to determine ownership, adequacy of facilities, and personnel qualifications. This section does not affect the requirement to complete a license application annually accompanied by an application fee as required by Section 111625.
- 20 SEC. 5. Section 111655 of the Health and Safety Code is amended to read:
  - 111655. The licensing provisions of this chapter shall not apply to any of the following:
  - (a) Any pharmacy that maintains establishments in conformance with provisions of the Pharmacy Law, Chapter 9 (commencing with Section 4000) of Division 2 of the Business and Professions Code, regulating the practice of pharmacy, and that is regularly engaged in dispensing prescription drugs or devices, upon prescriptions of any person licensed to administer the drugs or devices to patients under the care of the person in the course of his or her professional practice, and that does not manufacture, prepare, propagate, compound, or process drugs or devices for sale other than in the regular course of his or her business of dispensing or selling drugs or devices at retail.
- (b) Any pharmacy that solely engages in providing drugs or devices to a person licensed by law to administer 38 the drug or device for his or her use in the course of his 40 or her professional practice.

AB 764 — 8 —

 (e) Any pharmacy that solely provides drugs or devices to another pharmacy in order to meet a temporary inventory shortage.

- (d) Any person who is licensed by law to prescribe or administer drugs or devices and who manufactures, prepares, propagates, compounds, or processes drugs or devices solely for use in the course of his or her professional practice.
- (e) Any person who manufactures, prepares, propagates, compounds, or processes any drug or device solely for use in nonclinical research, teaching, or chemical analysis and not for sale.
- (f) Any wholesaler, as defined in Section 4038 of the Business and Professions Code.
- (g) Any other class of persons as the department may by regulation exempt from the application of this article upon a finding that licensing by a class of persons in accordance with this article is not necessary for the protection of the public health.
- (h) Any registered dispensing optician licensed pursuant to the provisions of Chapter 5.5 (commencing with Section 2550) of Division 2 of the Business and Professions Code, who is regularly engaged in dispensing or selling prescription lenses and frames, and not engaged in the manufacture, preparation, processing or assembling of lenses or frames for sale other than in the regular course of his or her business of dispensing or selling lenses or frames at retail.
- (i) Any person who has registered an establishment and listed all products in compliance with Section 360 of Title 21 of the United States Code and submits a copy of the federal registration and listing to the department in accordance with regulations established by the department.
- 35 SEC. 5. Section 110405 of the Health and Safety Code 36 is amended to read:
- 37 110405. An advertisement that is not unlawful under 38 Section 110390 is not unlawful under Section 110403 if it 39 is disseminated either one of the following:

**—9— AB 764** 

(a) Disseminated only to members of the medical, professions, or dental, pharmaceutical, or veterinary appears only in the scientific periodicals of these professions, or is disseminated only for the purpose of public health education by persons not commercially interested, directly or indirectly, in the sale of drugs or devices.

(b) An advertisement that a drug or device has a specific curative or therapeutic effect on a condition, 10 disorder, or disease listed in Section 110403 if the drug or device is approved or cleared for marketing for that specific curative or therapeutic effect through any of the 13 following means:

8

12

22

24

27

- 14 (1) A new drug application approved pursuant to 15 Section 111500 or Section 505 of the federal act (21 U.S.C. 16 Sec. 355).
- 17 (2) An abbreviated new drug application approved 18 pursuant to Section 505 of the federal act (21 U.S.C. Sec. 19
- 20 (3) A licensed biological product pursuant to Section 21 351 of the Public Health Service Act (42 U.S.C. Sec. 262).
- (4) An over the counter drug that meets 23 requirements of Part 330 of Title 21 of the Code of Federal Regulations.
- 25 (5) A new animal drug application approved under Section 512 of the federal act (21 U.S.C. Sec. 360b).
- (6) An abbreviated new animal drug application 28 approved pursuant to Section 512 of the federal act (21 U.S.C. Sec. 360b).
- 30 (7) A new device application approved pursuant to 31 Section 111550.
- 32 (8) A device premarket approval application approved under Section 515 of the federal act (21 U.S.C. 33 34 Sec. 360e).
- 35 (9) A determination of substantial equivalence for a 36 device pursuant to Section 513(f)(1) of the federal act (21) 37 U.S.C. Sec. 360c(i).
- SEC. 6. Section 110408 of the Health and Safety Code 38 39 is repealed.

**AB 764 — 10 —** 

1

5

9

10 11

12

13

15

17

27

28

110408. Whenever the department determines that an advance in medical science has made any type of self-medication safe and effective as to any of the conditions, disorders, or diseases named in Section 110403, the department shall, by regulation, authorize the advertisement of any such drug or device as having a curative or therapeutic effect for the disease, subject to conditions and restrictions as the department may consider necessary to the interests of public health.

SEC. 7. Section 111635 of the Health and Safety Code is amended to read:

111635. Prior to issuing or renewing a license required by Section 111615, the department shall inspect each place of business.

- (b) The department shall subsequently inspect the 16 place of business of each person licensed under Section 111615 once every two years. The department shall *inspections* to determine 18 conduct these 19 adequacy of facilities, personnel qualifications. and 20 Where the United States Food and Drug Administration 21 has conducted an inspection of the place of business 22 within the previous two years, the department shall use 23 the information obtained during that inspection rather 24 than conducting its own inspection pursuant to this subdivision. The department may, if necessary, inspect to additional information obtain needed to determine ownership, adequacy ofpersonnel facilities, and qualification.
- (c) The department may, in lieu of all or part of any 30 inspection required under this section, use information 31 from audits conducted pursuant to the provisions of the 32 International Standards Organization (ISO) 9000 series 33 or European (EN) 46000 series quality system standards, 34 or other information identified by the department by 35 regulation.